Drug Profile
Telacebec - Qurient Co
Alternative Names: Q-203Latest Information Update: 07 Feb 2023
Price :
$50
*
At a glance
- Originator Qurient Co
- Class Amides; Anti-inflammatories; Antibacterials; Antituberculars; Imidazoles; Piperidines; Pyridines; Small molecules
- Mechanism of Action Bacterial growth inhibitors; Electron transport complex III inhibitors; Leukotriene inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections; SARS-CoV-2 acute respiratory disease; Tuberculosis
- Phase I Buruli ulcer
Most Recent Events
- 03 Feb 2023 Telacebec licensed to Global Alliance for TB Drug Development worldwide (except South Korea, Russia and Commonwealth of Independent States (CIS) countries) for the treatment of Tuberculosis
- 07 Mar 2022 Phase-I clinical trials in Buruli-ulcer in South Korea (unspecified route) prior to March 2022 (Qurient pipeline, March 2022)
- 12 Feb 2022 Qurient Co terminates a phase-II trial due to its own decision in COVID-2019 infections in South Africa (PO) (NCT04847583)